Navigation Links
Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
Date:5/6/2009

CASTRES, France, May 6 /PRNewswire/ -- Pierre Fabre Dermatologie, specialised department of Pierre Fabre Laboratories, is proud to announce the launch of a set of clinical trials following the signature of an exclusive and worldwide licence agreement on July 10th 2008 with the University of Bordeaux. The contract covers the development, production and marketing of a paediatric beta-blocker for the treatment of severe infantile haemangioma with the intention of obtaining NDA-approval (New Drug Application) both for Europe and the USA. Patents were also applied for in this indication.

The efficacy of beta-blockers on haemangioma was discovered by Dr. Christine Leaute- Labreze, dermatologist in Pr. Alain Taieb's department in Bordeaux. "Effectiveness of this treatment has been demonstrated in several hundred children throughout the world. Rigorous clinical trials are, however, yet to be conducted to ascertain the efficacy and tolerance of this new therapeutic strategy, hence this agreement with Pierre Fabre Dermatologie, which would ensure safety and availability of the treatment."

This therapeutic breakthrough has been widely talked about, not only during scientific conferences but also through professional and general-interest press.

"This is a major discovery that will bring true therapeutic advance to patients affected by this highly apparent disease, which can be very severe and can have a strong impact on their quality of life and that of their parents. For this reason, we are highly honoured to have signed this agreement with the University of Bordeaux on severe haemangioma," specifies Jacques Fabre, General Manager of Pierre Fabre Dermocosmetique.

About haemangioma:

Infantile haemangioma refers to a vascular tumour highly prevalent in infants, with a 10% concurrency rate. Haemangioma occurs in the first months of life and is located on the face in 60% of cases
'/>"/>

SOURCE Pierre Fabre SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
2. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
3. Evotec Starts Phase II in Smoking Cessation with EVT 302
4. Synosia Starts Phase II Efficacy Trial For Rufinamide
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
6. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
7. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
10. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)...  The element of surprise has been a major ... without warning. Until now, epidemiologists had nothing to measure ... resulting in suboptimal responses to both the H1N1 pandemic ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 That ... virus gene structural changes have been found that invariably ...
(Date:11/21/2014)... England , Nov. 21, 2014   TRU-D SmartUVC ... will feature their superbug-killing UVC automated disinfection robot, TRU-D SmartUVC, ... this week from Nov. 23 to 26 at Stand 23. ... is the United Kingdom,s largest infection-related ... infection prevention societies to one of the leading events of ...
(Date:11/21/2014)... CA (PRWEB) November 20, 2014 Author ... Short Walk to the Other Side” published as ... “Award-Winning Finalist in the “Fiction: Short Story” category of ... Jeffrey Keen, President and CEO of USA Book News, ... mainstream and independent publishers, including Simon & Schuster, Penguin, ...
(Date:11/21/2014)... New York, NY (PRWEB) November 20, 2014 ... ) is now available as an open access journal ... cells with infrared fluorescent proteins to preserve photoresponsiveness in ... Two-color fluorescent in situ hybridization using chromogenic ... microfluidics chips for DNA, RNA, and protein electrophoresis , ...
Breaking Biology Technology:Viruses' Advantage of Surprise is Lost 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3
... SUNNYVALE, Calif., Aug. 5 Pharmacyclics, Inc. (Nasdaq: PCYC ... up to 22,500,000 shares of the Company,s common stock at a subscription ... on July 31, 2009. The Company increased the offering size on July ... to 22,500,000 shares. , , The subscription ...
... JEFFERSON, N.C., Aug. 5 Next Safety, Inc. (NSI) ... work in a pandemic environment. Next Safety is releasing for sale ... flu influenza A subtype H5N1. , , The ... became contagious. The Next Safety respirators are now being sold to ...
... , SANTA MONICA, Calif., Aug. 5 Cord ... stem cell preservation company ( http://www.cordblood-america.com ) ... families nationwide and internationally, said today it has retired $2.53M of ... in February and March of 2007 respectively, between CBAI and the ...
Cached Biology Technology:Pharmacyclics, Inc. Rights Offering Oversubscribed 2Pharmacyclics, Inc. Rights Offering Oversubscribed 3Next Safety Releases Advanced Respirator for Infectious Diseases 2Next Safety Releases Advanced Respirator for Infectious Diseases 3Cord Blood America Retires $2.53M Obligation 2Cord Blood America Retires $2.53M Obligation 3
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
(Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Study finds laundry detergent pods, serious poisoning risk for children 2
... neuroscience research programme that spans basic science all the ... tertiary hospitals and medical schools, and a national organisation ... Singapore. These are some of the new initiatives ... Council (BMS IAC) at their annual meeting today. ...
... An international team of Australian and Israeli researchers has ... moonlight sex event on Earth., An ancient light-sensitive gene ... of Excellence for Coral Reef Studies (CoECRS) that appears ... spawning of corals across a third of a million ...
... method of constructing artificial plant chromosomes from small rings ... transport multiple genes at once into embryonic plants where ... passed on to the next generation -- a long-term ... In the October 19, 2007, issue of PLoS-Genetics, ...
Cached Biology News:Phase 2 of Singapore's Biomedical Sciences Initiative gains momentum for clinical research 2Phase 2 of Singapore's Biomedical Sciences Initiative gains momentum for clinical research 3Phase 2 of Singapore's Biomedical Sciences Initiative gains momentum for clinical research 4Phase 2 of Singapore's Biomedical Sciences Initiative gains momentum for clinical research 5Phase 2 of Singapore's Biomedical Sciences Initiative gains momentum for clinical research 6Key found to moonlight romance 2Key found to moonlight romance 3Transgenics transformed 2Transgenics transformed 3
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
Request Info...
Request Info...
Non-Protein Peroxidase Stabilizer , 1 L...
Biology Products: